Articles tagged with Cancer Patients
Researchers at H. Lee Moffitt Cancer Center describe a promising new treatment combination for patients with non-small cell lung cancer, showing preliminary efficacy and improved tolerance compared to standard treatments.
A new drug, TAK-228, has demonstrated effectiveness in treating metastatic bladder cancer, slowing tumor growth and progression. The study found that four of seven patients showed a positive response to the treatment.
A recent study found that primary care physicians recommend health promotion to at least some cancer survivors, but oncologists and specialists rarely do. Cancer survivors face increased risks of cardiovascular disease if they don't adopt healthy lifestyles.
A recent study published in Journal of Adolescent and Young Adult Oncology found that 30% of young adult cancer patients (ages 18-39) tested positive for a breakdown product of cannabis. Cannabis users were more likely to be male and report having more severe symptoms, including pain and nausea.
Researchers are conducting a phase 1 clinical trial using CAR-T cells, which have been shown to attack and kill cancers. The goal is to learn more about how these super-powered immune cells interact with solid tumors to develop effective treatments for various types of cancer.
A team of researchers at Georgetown University Medical Center has identified a chain of molecules critical for pancreatic ductal adenocarcinoma (PDAC) growth and survival. Inhibiting this 'Yap' biological network may effectively regress early-stage PDAC, and pairing it with other drugs could halt more advanced stage tumors.
A clinical trial discovered that selinexor, a novel therapy, effectively knocked down bone marrow cancer in over a quarter of patients, including two who achieved complete remission. The treatment showed promise for patients resistant to multiple therapies and offered new hope for those with limited treatment options.
Researchers analyzed genomic data from 317 MCC patients and found two distinct populations with different genetic profiles and treatment responses. Immunotherapies showed high effectiveness in both groups, with better response rates when given early treatment.
Research published in Gut journal suggests a link between antibiotic use and increased risk of bowel cancer, particularly for cancers of the proximal colon. Conversely, rectal cancer risk was found to be lower among those prescribed antibiotics, possibly due to differences in gut microbiome activity.
The study aims to improve caregiver physical and emotional well-being, increase confidence for caregiving, and enhance patient outcomes. Researchers will use simulation-based learning to train 180 family caregivers, comparing results to a control group.
Researchers at Moffitt Cancer Center have discovered a new treatment approach that may help nearly a third of lung cancer patients with KRAS mutations. The combination therapy targets the MEK kinase and enhances anti-tumor immunity through cytokines TNFα and IFNγ.
A new study found that even low-intensity exercise was associated with a nearly 20% reduction in cancer progression or death in patients with advanced colorectal cancer. Patients who engaged in moderate exercise while undergoing chemotherapy tended to have delayed disease progression and fewer severe side effects from treatment.
The study examined 3,368 medical aid in dying prescriptions from Oregon (1998-2017) and Washington (2009-2017), finding that most patients were insured, non-Hispanic white individuals with cancer. The primary reasons for pursuing medical aid in dying were loss of autonomy, impaired quality of life, and loss of dignity.
Moffitt researchers identified three subtypes of squamous cell lung cancer (SCC) with distinct genetic, chromosomal, and protein alterations. The inflamed subtype is characterized by immune cell infiltration and higher PD-1 levels, while the redox subtype has altered oxidation-reduction signaling pathways. These subtypes did not correl...
Adults aged 85 years and older account for the fastest-growing age group in the US, with higher cancer incidence rates but lower screening and treatment rates. The most common cancers among this population are lung, breast, prostate, and colorectum, but late-stage diagnosis and poorer survival outcomes are also reported.
A study analyzing published research found Nordic walking reduces swelling and improves physical fitness in breast cancer patients. However, more well-designed studies are needed to explore its full potential.
Five postdoctoral scholars will collaborate with experts in physical and biomedical science to better understand the interplay between the immune system and cancers. The fellowships aim to develop new treatments using a patient's immune system to prevent, control, and treat cancer.
A study of UK patients diagnosed with colorectal cancer between 2006 and 2013 found that those under 50 experienced more non-specific symptoms before referral to specialists. Younger patients also had longer intervals between diagnosis and referral, highlighting a need for primary care awareness.
Scientists have developed a personalized platform called TARDIS that accurately detects circulating tumor DNA and signs of residual disease in breast cancer patients. The assay demonstrated a significant improvement in sensitivity, enabling earlier detection of tumors and monitoring patient response to chemotherapy.
A new 'liquid biopsy' blood test called TARDIS detects circulating tumor DNA in patient blood, enabling precise monitoring of disease progression and response to treatment. The test's high sensitivity could help plan surgical resection and radiation therapy after pre-operative therapy.
A liquid biopsy assay demonstrated high accuracy in detecting microsatellite instability (MSI) status in cancer patients, with an overall accuracy of 98.4%. The study showed that the assay could identify MSI-high tumors and predict clinical outcomes, offering potential benefits for personalized treatment planning.
A study published in Nature Immunology reveals that immune cells' activation state prior to anti-PD-1 therapy is crucial for cancer response. The researchers found a way to overcome resistance by activating T cells through vaccines, suggesting a new approach to enhance PD-1 inhibitors.
The GW Cancer Center is conducting a randomized, placebo-controlled phase III trial to investigate cemiplimab's safety and effectiveness in preventing recurrence and metastasis in high-risk cutaneous squamous cell carcinoma. The study aims to enroll over 400 participants worldwide.
A new study has found that elderly cancer patients who are HIV-positive have poorer outcomes compared to those without the virus. The research found higher mortality rates from breast and prostate cancers among HIV-infected patients.
Researchers compared outcomes in patients with and without HIV who received stage-appropriate cancer treatment after a cancer diagnosis at age 65. The study found no significant difference in overall survival between the two groups, suggesting that age alone may not be a determining factor in cancer treatment outcomes.
A new study has found that psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer. Patients who experienced stress-related disorders or stressful life events were 33% more likely to die from the disease compared to those who did not report stress.
The National Cancer Institute has recognized Sylvester Comprehensive Cancer Center as a top-tier US cancer center due to its outstanding research and clinical care. The designation is a testament to the dedication of every member of the cancer center.
A breakthrough new drug CBL0137 has proven effective in mice treated with chemotherapy and is being tested as a potential treatment for all types of cancer, including solid tumours. The drug works by reactivating the body's P53 pathway to kill off damaged cells.
Researchers discovered that natural killer (NK) cells can express PD-L1 and provide anti-tumor activity when treated with checkpoint inhibitors. PD-L1+ NK cells can control tumor growth by killing tumors and secreting cytokines, providing a new immunotherapeutic avenue.
Antonio Giordano, a Hollings Cancer Center clinical scholar, is researching novel treatments for triple-negative breast cancer. He aims to develop a PLK1-inhibitor drug and explore the role of tumor-infiltrating lymphocytes in prognosis.
Research from St. Jude Children's Research Hospital found a link between inherited BRCA2 mutations and an increased risk of childhood non-Hodgkin lymphoma. The study analyzed data from 1,380 lymphoma survivors and found that members with BRCA2 mutations were more likely to develop the disease.
A study published in JAMA Oncology reports higher than expected five-year survival rates for patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer treated with nivolumab. The treatment showed durable responses and improved outcomes for patients without cancer-related symptoms.
A new AI tool developed by Dana-Farber Cancer Institute can extract high-value cancer outcomes from unstructured radiology reports with comparable accuracy to human reviewers. The tool, trained on over 14,000 imaging reports, was able to replicate human assessments of disease-free survival and progression-free survival.
A new, non-invasive bladder cancer treatment method uses a 'liquid biopsy' from urine to identify molecular underpinnings of each patient's unique bladder cancer. The technique, called conditional reprogramming or CR, has shown promising results in detecting and treating the disease.
The FDA has approved erdafitinib as a targeted therapy for patients with advanced bladder cancer who have specific gene mutations in the FGFR3 gene. The drug achieved a 40% overall response rate and was well-tolerated, offering an alternative to existing treatments.
Researchers at the University of Maryland and National Cancer Institute identified 12 distinct gene-pair relationships in tumor cells that could be targeted for cancer therapy. These relationships were associated with varying levels of expression in the two genes and correlated with cancer patient survival.
A global report found that one in three cancer patients struggle to access psychological support, with 34% saying it was not available despite needing it. The survey also identified key areas for improvement, including swift diagnosis, information-sharing, and integrated multidisciplinary care.
Tiny devices based on microfluidics can analyze bodily fluids to detect early signs of cancer, enabling widespread screening. They also help develop personalized treatments by predicting patient responses to drug candidates.
ASHG honors Drs. Weitzel and Blazer for their exceptional contributions to cancer genomics education, impacting thousands of patients globally. Their initiatives have prepared clinicians for leadership roles in translational research and improved healthcare outcomes.
A team at Fred Hutchinson Cancer Research Center has identified a gene called DUX4 that can prevent the immune system from recognizing and attacking cancer cells. This discovery suggests that blocking the activity of this gene might increase the success of immunotherapy treatments for a wide range of cancers.
Researchers discovered that leukemia stem cells suppress NKG2D-L proteins, evading the immune system. By inhibiting PARP1, these cells can be recognized and eliminated by NK cells.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers discovered a cellular pathway linked to cancer that may benefit patients with hepatocellular carcinoma by reducing side effects and extending immunotherapy duration. The study found that blocking the IL-6/JAK1 pathway could resolve immunotherapy side effects and improve treatment outcomes.
Researchers have developed an AI algorithm that can analyze breast ultrasound images to detect cancer with high accuracy. The algorithm uses synthetic data to train itself, achieving nearly 100% classification rate on real-world images.
Researchers have identified an enzyme called LPCAT1 that plays a key role in tumor growth by changing the phospholipid composition of cancer cells' plasma membranes. When genetically depleted in mice, malignancies shrank dramatically, suggesting LPCAT1 as a potential new drug target for various cancer types.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers have identified a new cell growth pathway that could lead to better treatments for metastatic cancers. The study found that the mEAK-7 gene is highly expressed in metastatic non-small cell lung cancer cells and plays a key role in cancer metastasis.
Researchers are testing a therapy called bermekimab, which blocks inflammation and pain-causing molecules in the immune system. The trial aims to improve outcomes in lung, pancreatic and ovarian cancer patients, with the goal of reducing symptoms such as weight loss and decreased mobility.
A worldwide coalition of researchers has agreed that light therapy is an effective intervention for preventing oral mucositis in head and neck cancer patients. The new guidelines recommend photobiomodulation therapy, a low-dose light therapy, to prevent the painful ulcers resulting from radiation therapy.
City of Hope scientists develop blood test to forecast breast cancer recurrence risk in patients with solid tumors. The innovative approach aims to personalize treatment strategies and improve patient outcomes.
A new probe has been developed to help surgeons detect cancer cells during surgery, with the potential to improve surgical outcomes for patients. The probe uses fluorescence imaging and has been published in Chemical Science, a study led by RCSI researchers.
A phase III trial found that a three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer. The treatment resulted in a median overall survival of 9 months compared to 5.4 months for standard therapy.
Researchers at Stanford University School of Medicine have developed a computer algorithm that integrates various predictive data to generate a single, dynamic risk assessment for cancer patients. The algorithm, termed CIRI, outperformed standard methods in predicting patient outcomes and identifying better treatment options.
A study found that a naturally occurring strain of the common cold, coxsackievirus CVA21, can target and destroy bladder cancer cells without causing harm to healthy cells. The treatment showed significant reduction in tumour burden and removal of disease in one patient after just one week.
A new IOF review emphasizes the importance of long-term follow-up to maintain bone health in childhood cancer survivors. The study highlights the need for careful monitoring and management to prevent premature onset of low bone mineral density and improve fracture risk.
A new study shows that niraparib can extend life for women with ovarian cancer who have undergone multiple rounds of chemotherapy. The study found that 27% of patients responded well to the drug and averaged 9.2 months until disease progression, offering hope for a meaningful treatment option.
A new study found that gastric cancer is affecting more young Hispanic people in the US, with poorer outcomes than older patients. Women under 40 were more likely to have diffuse-type tumours and stage IV disease at diagnosis, leading to a median overall survival of just 7 months.
A study by the National Cancer Institute found a clear dose-response relationship between radioactive iodine treatment and long-term risk of death from solid cancers, including breast cancer. The study estimated that for every 1,000 patients treated with standard doses, about 20-30 additional solid cancer deaths would occur.
The foundation awarded Continuation Grants to five Damon Runyon Clinical Investigators, providing an additional two years of funding totaling $400,000. The recipients are conducting patient-oriented cancer research with the goal of finding cures for cancer diagnosis, prevention and treatment.
A 65-year follow-up study of nearly 7,000 Norwegian patients with multiple sclerosis found an overall risk of developing cancer 14% higher than the general population. Respiratory cancer risk was particularly high at 66%, while urinary and central nervous system cancer risks were also significantly increased.